Gilead Sciences, Inc.'s Veklury (remdesivir) is the first and only drug approved by the US Food and Drug Administration for the treatment of COVID-19, although it is already widely used for treating the infection in hospitalized patients. Veklury was granted an emergency use authorization in May for the treatment of patients with COVID-19 requiring hospitalization. (Also see "Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US" - Scrip, 30 June, 2020.)
The antiviral was one of the first options to become available to patients hospitalized with COVID-19, along with the steroid dexamethasone. While supply was constrained initially, Gilead has ramped up the manufacturing capacity for Veklury
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?